Sign in
DRRX Stock Price, Chart, Stats & News
DURECT Corporation
Save
59.31M
Market cap
–
Current P/E
–
Forward P/E
DRRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 80.59% |
Operating margin | -531.54% |
Pretax margin | -428.81% |
Net margin | -110.48% |
Effective tax rate | – |
ROA | -27.86% |
ROE | -70.85% |
D/E | 0.44x |
Interest coverage ratio | -45.97x |
DRRX valuation
P/E | – |
P/S | 18.84x |
P/B | 15.06x |
P/CF | -4.25x |
P/FCF | -4.25x |
P/OCF | -4.25x |
PEG | -0.51x |
EV multiple | -4.32x |
About
DURECT Corporation is a biopharmaceutical enterprise dedicated to the research and development of innovative medicines, leveraging its epigenetic regulator and pharmaceutical platforms. The company provides the ALZET product range, which includes osmotic pumps and associated accessories vital for research studies conducted on mice, rats, and other laboratory animals. In its development pipeline, DURECT is advancing larsucosterol (DUR-928), an endogenous, orally administered small molecule.
Similar securities
Based on sector and market capitalization
Report issue